This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Snow, A. D. Articles by Kimata, K. Search for Related Content PubMed PubMed Citation Articles by Snow, A. D. Articles by Kimata, K.

American Journal of Pathology, Vol 144, 337-347, Copyright © 1994 by American Society for Investigative Pathology

REGULAR ARTICLES

Heparan sulfate proteoglycan in diffuse plaques of hippocampus but not of cerebellum in Alzheimer's disease brain

AD Snow, RT Sekiguchi, D Nochlin, RN Kalaria and K Kimata
Department of Pathology, University of Washington, Seattle 98195.

Previous studies have shown the basement membrane form of heparan sulfate proteoglycan (HSPG) known as perlecan, co-localized to beta- amyloid protein (A beta)-containing amyloid deposits in brains of patients with Alzheimer's disease (AD) and Down's syndrome. Although HSPG was localized to diffuse A beta plaques in hippocampus, amygdala, and neocortex, it is not known whether they are present in diffuse A beta plaques in cerebellum. In the present study, Alcian blue staining and immunocytochemical techniques were used to determine whether highly sulfated glycosaminoglycans (GAGs) and/or HSPG (perlecan) were also present in diffuse A beta plaques of cerebellum. Tissues from cases of AD were examined for the co-localization of highly sulfated GAGs, HSPGs, and A beta in diffuse plaques in cerebellum in comparison with hippocampus. Consecutive serial sections of AD brain tissue were stained or immunostained with 1) the modified Bielschowsky stain; 2) a polyclonal antibody directed against synthetic A beta (1-40); 3) Congo red; 4) Alcian blue (pH 5.7) with varying concentrations of magnesium chloride for identification of sulfated and highly sulfated GAGs; and 5) polyclonal and monoclonal antibodies recognizing either the core protein or a specific GAG epitope on perlecan. All cases (7 of 7) of AD contained diffuse A beta plaques in the cerebellum as identified by positive Bielschowsky staining and A beta immunoreactivity. None of these cases demonstrated positive Alcian blue staining (at 0.3 and 0.7 mol/L MgCl2), HSPG, or HS GAG immunoreactivity in the same diffuse cerebellar plaques on adjacent serial sections. However, Alcian blue staining, HSPG, and/or HS GAG immunoreactivity were observed in blood vessel walls, choroid plexus, and within Purkinje cells, suggesting that the techniques used were reliable and specific. In cerebellum, all plaques containing amyloid cores that were Congo red-positive were also positive for highly sulfated GAGs (by Alcian blue staining at 0.7 mol/L MgCl2) and HSPG (both core protein and GAG chain) immunoreactivity. Even though HSPG immunoreactivity was not present in cerebellar diffuse plaques, all cases (4 of 4) examined demonstrated HSPG (both core protein and GAG chain) immunoreactivity in diffuse A beta plaques in hippocampus. Therefore, by Alcian blue staining and immunocytochemical methods, highly sulfated GAGs and HSPGs are not present in A beta diffuse plaques in cerebellum. Since previous studies indicate that the cerebellum contains relatively few amyloid-containing plaques in comparison with diffuse plaques, these studies suggest that HSPG may be an essential component needed for amyloid formation and/or persistence in brain as observed in cortical areas.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				A. E. Reyes, M. A. Chacon, M. C. Dinamarca, W. Cerpa, C. Morgan, and N. C. Inestrosa Acetylcholinesterase-A{beta} Complexes Are More Toxic than A{beta} Fibrils in Rat Hippocampus: Effect on Rat {beta}-Amyloid Aggregation, Laminin Expression, Reactive Astrocytosis, and Neuronal Cell Loss Am. J. Pathol., June 1, 2004; 164(6): 2163 - 2174. [Abstract] [Full Text] [PDF]

				Z. Scholefield, E. A. Yates, G. Wayne, A. Amour, W. McDowell, and J. E. Turnbull Heparan sulfate regulates amyloid precursor protein processing by BACE1, the Alzheimer's {beta}-secretase J. Cell Biol., October 13, 2003; 163(1): 97 - 107. [Abstract] [Full Text] [PDF]

				M. M. Verbeek, I. Otte-Holler, J. van den Born, L. P. W. J. van den Heuvel, G. David, P. Wesseling, and R. M. W. de Waal Agrin Is a Major Heparan Sulfate Proteoglycan Accumulating in Alzheimer’s Disease Brain Am. J. Pathol., December 1, 1999; 155(6): 2115 - 2125. [Abstract] [Full Text] [PDF]

				D. W. Dickson Microglia in Alzheimer's Disease and Transgenic Models : How Close the Fit? Am. J. Pathol., June 1, 1999; 154(6): 1627 - 1631. [Full Text] [PDF]

				D. J. Watson, A. D. Lander, and D. J. Selkoe Heparin-binding Properties of the Amyloidogenic Peptides Abeta and Amylin. DEPENDENCE ON AGGREGATION STATE AND INHIBITION BY CONGO RED J. Biol. Chem., December 12, 1997; 272(50): 31617 - 31624. [Abstract] [Full Text] [PDF]

				R. Gupta-Bansal, R. C. A. Frederickson, and K. R. Brunden Proteoglycan-mediated Inhibition of Abeta Proteolysis J. Biol. Chem., August 4, 1995; 270(31): 18666 - 18671. [Abstract] [Full Text] [PDF]

				K. Tsuchida, J. Shioi, S. Yamada, G. Boghosian, A. Wu, H. Cai, K. Sugahara, and N. K. Robakis Appican, the Proteoglycan Form of the Amyloid Precursor Protein, Contains Chondroitin Sulfate E in the Repeating Disaccharide Region and 4-O-Sulfated Galactose in the Linkage Region J. Biol. Chem., September 28, 2001; 276(40): 37155 - 37160. [Abstract] [Full Text] [PDF]